Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Huang T-, Shen Z-, Sleckman BP, Tyler JK. The histone chaperone ASF1 regulates the activation of ATM and DNA-PKcs in response to DNA double-strand breaks. Cell Cycle. 2018;17(12):1413-1424.

Avecilla ST, Goss C, Marionneaux SM, Wright DR, Leiva TD, Tonon J-, et al. Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE). Adv Cell Gene Ther. 2018;1(2).

Zhang W, Shu Q, Zhao Z, Fan J, Lyon CJ, Zelazny AM, et al. Antigen 85B peptidomic analysis allows species-specific mycobacterial identification. Clin Proteomics. 2018;15:1.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, Van Besien K, et al. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leuk Lymphoma. 2018;59(1):256-258.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontan L, et al. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discov. 2018;8(12):1632-1653.

Omay SB, Chen Y-, Almeida JP, Ruiz-Treviño AS, Boockvar JA, Stieg PE, et al. Do craniopharyngioma molecular signatures correlate with clinical characteristics? J Neurosurg. 2018;128(5):1473-1478.

Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M, et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol. 2018;138(1):183-190.

Huang J, Diaz-Meco MT, Moscat J. The macroenviromental control of cancer metabolism by p62. Cell Cycle. 2018;17(17):2110-2121.

Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, et al. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018;59(12):2829-2835.

Ellis L, Loda M. LSD1: A single target to combat lineage plasticity in lethal prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4530-4531.